Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy-Reference-Cited by-同舟云学术

Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy

Published:2022-05-26 Issue:1 Volume:11 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Petrazzuolo Adriana¹²,Maiuri M. Chiara¹²,Zitvogel Laurence³⁴⁵⁶^ORCID,Kroemer Guido¹²⁷^ORCID,Kepp Oliver¹²^ORCID

Affiliation:

1. Team “Metabolism, Cancer & Immunity”, Centre de Recherche des Cordeliers, INSERM UMRS1138, Université Paris Cité, Sorbonne Université, Paris, France

2. Cell Biology and Metabolomics platforms, Gustave Roussy Cancer Campus, Villejuif, France

3. Faculty of Medicine, University Paris Saclay, Kremlin Bicêtre, France

4. Gustave Roussy Cancer Campus (GRCC), Clinicobiome, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France

5. Institut National de la Santé et de la Recherche Medicale (INSERM) U1015, Villejuif, France

6. Center of Clinical Investigations in Biotherapies of Cancer (CICBT) Biotheris 1428, Villejuif, France

7. Department of Biology, Institut du Cancer Paris CARPEM, Hôpital Européen Georges Pompidou, AP-HP, Paris, France

Funder

funding

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2022.2077898

Reference213 articles.

1. Intercalators as Anticancer Drugs

2. Nitrogen mustard: The origin of chemotherapy for cancer

3. The Search of DNA-Intercalators as Antitumoral Drugs: What it Worked and What did not Work

4. Nitrogen-mustard therapy for hodgkin's disease, lymphosarcoma, the leuke-mias, and other disorders

5. LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MonoTip C18 pipette tip solid-phase extraction coupled with liquid chromatography-tandem mass spectrometry enables rapid and automated therapeutic drug monitoring of tyrosine kinase inhibitors;Arabian Journal of Chemistry;2024-10

2. Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential;Molecules;2024-09-09

3. Sorafenib safety evaluation: Real-world analysis of adverse events from the FAERS database;Heliyon;2024-09

4. Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma;OncoImmunology;2024-03-03

5. Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R;Communications Chemistry;2024-01-03